The Internationally Society on Thrombosis and Haemostasis (ISTH) and the European Association for Haemophilia and Allied Disorders (EAHAD) have announced an educational partnership to collaborate on components of the ISTH Gene Therapy in Hemophilia Education Initiative.read more…
The European Association for Haemophilia and Allied Disorders joined the European Hematology Association and other medical societies and patient advocates across disciplines to call for urgent action to make clinical trials less bureaucratic and more patient-centered, efficient and cheaper.read more…
Throughout the summer, members of our Physiotherapists Committee presented the “Super-Six Challenge for Haemophilia” focusing on the ankle, the knee, and the elbow, as part of the European Haemophilia Consortium’s #thisway online campaign.read more…
The EAHAD Nurse Committee currently has one vacant spot and is inviting nurses involved in haemophilia and bleeding disorders care to apply. The position is for a three-year term that would begin in February 2021.read more…
After careful consideration, the EAHAD 2021 Organising Committee has decided to make the upcoming EAHAD 2021 Congress a fully virtual event, taking place from 3 until 5 February 2021.read more…
Today, 15 July 2020, the European Association for Haemophilia and Allied Disorders together with 69 other thrombosis, haematology and patient safety organisations, published a Consensus Statement on the increased risk of deadly blood clots in Covid-19 patients.read more…
The 2019 EAHAD Annual Report has just been published. In it, readers will find information on all EAHAD-related activities of the past year. read more…
The European Association for Haemophilia and Allied Disorders (EAHAD) and European Haemophilia Consortium (EHC) have become aware of two deaths in patients with X-linked myotubular myopathy (XLMTM) on an AAV8-based gene therapy (AT132) in the phase 1/2 ASPIRO clinical trial conducted by Audentes, a subsidiary of Astellas. EHC and EAHAD are closely monitoring developments in this area due to this adeno-associated viral vector (AAV8) also being used in haemophilia gene therapy trials.read more…
The Covid-19 pandemic has caused a multi-dimensional crisis: medical, psychological, economic, occupational, and educational and more. People with bleeding disorders have suffered anxiety and concern regarding the influence of Covid-19 on their condition as well as uncertainty as to whether their treatments will continue to be accessible during this pandemic.read more…
Hosted by Prof. Michael Makris and with three insightful presentations by Prof. Víctor Jiménez Yuste, Prof. Flora Peyvandi, and Prof. Cedric Hermans, the EAHAD Webinar on Covid-19 and Haemophilia (originally streamed on Tuesday 2 June 2020) is now available for everyone to watch.read more…
